BioPharma Credit PLC

LSE:BPCP Stock Report

Market Cap: UK£803.7m

BioPharma Credit Past Earnings Performance

Past criteria checks 2/6

BioPharma Credit has been growing earnings at an average annual rate of 7.7%, while the Capital Markets industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.9% per year. BioPharma Credit's return on equity is 8.9%, and it has net margins of 80.2%.

Key information

7.7%

Earnings growth rate

7.9%

EPS growth rate

Capital Markets Industry Growth16.3%
Revenue growth rate6.9%
Return on equity8.9%
Net Margin80.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BioPharma Credit makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:BPCP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24136109270
31 Mar 24136109270
31 Dec 23136108270
30 Sep 23178147310
30 Jun 23221185360
31 Mar 23219184360
31 Dec 22218182360
30 Sep 22173146270
30 Jun 22128109190
31 Mar 2211697190
31 Dec 2110485190
30 Sep 2110989200
30 Jun 2111493210
31 Mar 2111291210
31 Dec 2011089210
30 Sep 2011186250
30 Jun 2011283300
31 Mar 20132103290
31 Dec 19151122290
30 Sep 19146119260
30 Jun 19142115240
31 Mar 1912093230
31 Dec 189770230
31 Dec 17342770

Quality Earnings: BPCP has high quality earnings.

Growing Profit Margin: BPCP's current net profit margins (80.2%) are lower than last year (83.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BPCP's earnings have grown by 7.7% per year over the past 5 years.

Accelerating Growth: BPCP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BPCP had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Capital Markets industry average (4.4%).

Return on Equity

High ROE: BPCP's Return on Equity (8.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 06:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioPharma Credit PLC is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew HoseJefferies LLC
Sachin SaggarStifel, Equities Research